Mitsuru Sugimoto,Tadayuki Takagi,Rei Suzuki,Naoki Konno,Hiroyuki Asama,Yuki Sato,Hiroki Irie,Ko Watanabe,Jun Nakamura,Hitomi Kikuchi,Mika Takasumi,Minami Hashimoto,Takuto Hikichi,Hiromasa Ohira
Mitsuru Sugimoto,Tadayuki Takagi,Rei Suzuki,Naoki Konno,Hiroyuki Asama,Yuki Sato,Hiroki lrie,Ko Watanabe,Jun Nakamura,Hitomi Kikuchi,Mika Takasumi,Minami Hashimoto,Hiromasa Ohira,Department of Gastroenterology,Fukushima Medical University,School of Medicine,Fukushima City,Fukushima Prefecture 960-1295,Japan
Ko Watanabe,Jun Nakamura,Hitomi Kikuchi,Minami Hashimoto,Takuto Hikichi,Department of Endoscopy,Fukushima Medical University Hospital,Fukushima City,Fukushima Prefecture 960-1295,Japan
Abstract
Key words: Endoscopic retrograde cholangiopancreatography;Pancreatic stent;Postendoscopic retrograde cholangiopancreatography pancreatitis;Meta-analysis
Endoscopic retrograde cholangiopancreatography (ERCP) occupies an important place in the endoscopic treatment and investigation of pancreatic and biliary diseases.However,post-ERCP pancreatitis (PEP) is a severe adverse event.Several past studies have reported that the occurrence of PEP was observed in 0.4%-5.6% of patients[1-8].Additionally,the fatality rate of PEP was 0%-0.1%[4,6-8].
The risk factors shown to influence PEP occurrence in past reports were previous history of pancreatitis or PEP,two or more pancreatography procedures,sphincter of Oddi dysfunction (SOD),age younger than fifty years,female sex,difficulty of biliary cannulation,biliary sphincter balloon dilation,and precut sphincterotomy[7-15].However,the usefulness of pancreatic stent (PS) placement for PEP has been reported in these high-risk patients[16-55].Several prospective randomized controlled trials(RCTs) were discussed in these reports.Some RCTs showed the efficacy of PS placement in preventing PEP[19,20,22,26,27,30,45,51-53,55].In addition,six meta-analyses were performed on this topic.The insertion of a PS was recommended in all of the metaanalyses[35,38,56-59].However,the RCTs involved in these meta-analyses were varied.In addition,two meta-analyses involved non-RCTs[38,59].In a study included in the two meta-analyses,the no stent group was not randomized[31].Therefore,we performed a meta-analysis limited to full-text articles and excluding any RCTs of special cases (for example,ampullectomy cases,only abstracts,etc.,).In addition,we included new RCTs in this meta-analysis.
We conducted a meta-analysis data search according to PRISMA statement guidelines[60].MS and TT performed literature retrieval using the MEDLINE,PubMed,Cochrane Library databases.The retrieval was limited to reports written in English.The following keywords were used for the search:“pancreatic stent” and “post-ERCP pancreatitis”.
The studies that met the following criteria were selected:(1) RCTs comparing patients who received a PS for the prevention PEP and patients who did not receive a PS during ERCP;(2) Full-length articles;and (3) Articles written in English.We excluded studies that met the following criteria:(1) Case reports;(2) Case series;(3)Retrospective case control studies;and (4) Studies on endoscopic ampullectomy,because the procedure considerably changes the form of the Vater papilla.Moreover,we performed a manual search of reports cited in the extracted articles to discover any additional reports.
The data extracted were as follows (Tables 1 and 2):(1) Study data (first author,year of publication,country);(2) Patient characteristics (age,sex,number of patients who received a PS,number of patients who did not receive a PS);and (3) Factors related to ERCP procedures (type of PS,success rate of PS insertion,occurrence of PEP,severity of PEP,severity criteria of PEP).
The publication bias for the obtained data was assessed using funnel plots.
The meta-analysis was performed using The EZR (Saitama Medical Center,Jichi Medical University,Saitama,Japan)[61].The homogeneity of each study was judged by determining theI2value.AnI2value ≤ 25% was considered to have no statistical heterogeneity.AnI2value of 25%-50% was treated as low statistical heterogeneity,and anI2value of 50%-75% was treated as moderate statistical heterogeneity.AnI2value > 75% was considered to have high statistical heterogeneity.A fixed-effects model was used if extracted studies had low heterogeneity.A random-effects model was used if the extracted studies were heterogeneous.APvalue < 0.05 indicated a significant difference.
A total of 369 articles were identified by searching MEDLINE,Cochrane Library and PubMed.Of these reports,80 studies were excluded because of duplication.In addition,279 studies were excluded according to the selection criteria described above,as determined from the title and abstract.Finally,11 studies were included in this meta-analysis (Figure 1).
All of these studies were RCTs published between 1993 and 2016.A total of 1475 patients were included in the studies,and of whom,734 patients underwent insertion of PS,and 741 patients did not have a PS inserted.In some studies,proteinase inhibitors or antibiotics were administered as other prophylaxis;however,rectal indomethacin was not used in any study.All patient characteristics are shown in Table 1,and ERCP-related procedures are shown in Table 2.
In the RCTs,with the exception of two studies by Smithlineet al[55]and Fazelet al[52],PEP was defined according to Cotton's criteria[62].In these RCTs,new abdominal pain after ERCP with elevated serum amylase no less than three times the normal upper limit in 24 h was diagnosed as PEP.In the study by Smithlineet al[55],abdominal pain with elevated serum lipase or amylase no less than two times the normal upper limit was diagnosed as PEP.In the study by Fazelet al[52],epigastric and umbilical pain with elevated serum amylase no less than two times the normal upper limit was diagnosed as PEP.
The severity of PEP was classified according to Cotton's criteria in almost all RCTs[62](Table 2).In the criteria,mild pancreatitis was defined as an extension of planned hospitalization of two to three days.Moderate pancreatitis was defined as anextension of planned hospitalization of four to ten days.Severe pancreatitis was defined as an extension of planned hospitalization of more than ten days with or without bleeding or a pseudocyst requiring intervention.
Table 1 Patient characteristics of selected studies
PEP was observed in all studies;it occurred in 39 (5.3%) patients who underwent PS insertion,and on the other hand,it occurred in 141 (19%) patients who did not have a PS inserted.The heterogeneity among the included studies was low (I2= 31%,P=0.15);therefore,we selected a fixed-effects model.The occurrence of PEP was significantly lower in patients who received a PS than in the patients who did not receive a PS (OR = 0.32;95%CI:0.23-0.45;P< 0.001;Figure 2).
We also evaluated severe PEP between the stent group and the no stent group.The occurrence of severe PEP was not observed in the stent group;however,the occurrence of severe PEP was observed in 8 (1.3%) patients who did not undergo PS insertion.Statistical heterogeneity was not seen in the included studies (I2= 0%,P=0.99);therefore,a fixed-effects model was chosen.The occurrence of severe PEP was significantly lower in the stent group than in the no stent group (OR = 0.24;95%CI:0.06-0.94;P= 0.04;Figure 3).
Egger's test of funnel plot asymmetry showed publication bias (P= 0.009;Figure 4).The funnel plot was asymmetric,and we found that negative studies with a smaller number of subjects were missing.
In this meta-analysis,prophylactic PS placement was efficient for preventing PEP.This result is the same as that in each previous RCT that was included in this metaanalysis.In addition,this meta-analysis proved that prophylactic PS placement prevented the occurrence of severe PEP.
In the eleven RCTs in this meta-analysis,ten RCTs indicated that prophylactic PS placement decreased the occurrence of PEP[19,20,22,26,27,30,45,51-53].However,Smithlineet al[55]reported that prophylactic main pancreatic duct stenting is not recommended for the prevention of PEP[55].The different results among the RCTs was influenced by the small sample size.In addition,there were far fewer patients with severe PEP.Therefore,the occurrence of severe PEP was not significantly different between the stent group and the no stent group in any of the included studies.On the other hand,severe PEP was not observed in the stent group in the included RCTs.These results indicated that prophylactic PS might prevent not only total PEP but also severe PEP.
The efficacy of prophylactic PS for preventing severe PEP was not statistically proven in any RCT.However,six meta-analyses were previously performed onprophylactic PS to prevent PEP.Additionally,two of the six meta-analyses also reported that prophylactic PS did not significantly prevent severe PEP[56,58].As more cases about prophylactic PS were reported,two meta-analyses performed by Mazakiet al[57,59]proved that prophylactic PS was efficient for preventing severe PEP.The second recent meta-analysis was carried out by Shiet al[35]and involved only full-text articles and excluded reports with only abstracts.However,the efficacy of prophylactic PS for preventing severe PEP was not shown in the meta-analysis.In the current meta-analysis,we included only full-text articles.As a result,PS was found to be efficient for preventing severe PEP.The addition of new RCTs and exclusion of RCTs on special cases such as ampullectomy[63]may have contributed to the definitive results of this meta-analysis.
Table 2 The factors related to the endoscopic retrograde cholangiopancreatography procedures of selected studies
This study has some limitations.First,all RCTs involved in this meta-analysis were written in English.Second,the type of PS was different in each RCT.Third,publication bias existed in this study.In the future,we hope that the accumulation of a greater number of relevant RCTs will overcome this bias.
In conclusion,prophylactic PS was useful for preventing not only PEP but also severe PEP.
Figure 1 The flowchart of the article selection process.
Figure 2 Forest plot of post-endoscopic retrograde cholangiopancreatography pancreatitis.
Figure 3 Forest plot of severe post-endoscopic retrograde cholangiopancreatography pancreatitis.
Figure 4 Funnel plot of post-endoscopic retrograde cholangiopancreatography pancreatitis occurrence.
Endoscopic retrograde cholangiopancreatography (ERCP) occupies an important place in the endoscopic treatment and investigation of pancreatic and biliary diseases.However,post-ERCP pancreatitis (PEP) is a severe adverse effect.To prevent PEP,prophylactic pancreatic stent (PS)placement has been recommended based on the results of several randomized controlled trials(RCTs).
Prior meta-analyses have shown that prophylactic PS was useful for preventing PEP.However,abstract reports and patients who underwent endoscopic ampullectomy were included in the previous analyses.The efficacy of PS for preventing severe PEP was different in each metaanalysis.Therefore,we performed the current meta-analysis,which included only full-text articles,and added new findings.
In this meta-analysis,we evaluated the efficacy of prophylactic PS for the prevention of PEP.
We identified the included RCTs by searching MEDLINE,Cochrane Library and PubMed.Among the retrieved reports,11 studies were included in this meta-analysis.The occurrence of PEP and severe PEP was evaluated.
The rates of PEP and severe PEP occurrence were significantly lower in patients who received a PS than in patients who did not receive a PS.
Prophylactic PS was useful not only for preventing PEP but also for preventing severe PEP.
This meta-analysis proved that prophylactic PS prevented severe PEP.This result will contribute to a reduction in PEP and severe PEP in patients undergoing ERCP.
World Journal of Meta-Analysis2019年5期